Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells

Cell Cycle

Volumn 11, Issue 7, 2012, Pages 1455-1467

  Belleudi, Francesca ^a   Marra, Emanuele ^b   Mazzetta, Francesca ^a   Fattore, Luigi ^a   Giovagnoli, Maria Rosaria ^a   Mancini, Rita ^a   Aurisicchio, Luigi ^b,c   Torrisi, Maria Rosaria ^a,d   Ciliberto, Gennaro ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Takis srl   (Italy)

^c Grande Ospedale Metropolitano   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Antibodies; Epitope mapping; ErbB3; Internalization; Melanoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A2; MONOCLONAL ANTIBODY A3; MONOCLONAL ANTIBODY A4; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; MELANOMA CELL; PROTEIN BINDING; PROTEIN DEGRADATION;

EID: 84860337685     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19861     Document Type: Article

References (37)

1. Kaufman HL. The melanoma book, a complete guide to prevention and treatment. Penguin Group: USA 2005.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782.
4. Poulikakos PI, Rosen N. Mutant BRAF melanomas - dependence and resistance. Cancer Cell 2011; 19:11-5; PMID:21251612; http://dx.doi.org/10.1016/ j.ccr.2011.01.008.
5. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77:400-10; PMID:20130423; http://dx.doi.org/10.1159/000279388.
6. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117-34; PMID:20602996; http://dx.doi.org/10.1016/j.cell.2010.06. 011.
7. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117:2051-8; PMID:17671639; http://dx.doi.org/10.1172/JCI32278.
8. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656.
9. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284:54-65; PMID:12648465; http://dx.doi.org/10.1016/S0014-4827(02)00101-5.
10. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-67; PMID:10880430; http://dx.doi.org/10.1093/emboj/19.13.3159.
11. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10:1813-21; PMID:7538656.
12. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003; 100:8933-8; PMID:12853564; http://dx.doi.org/10.1073/pnas.1537685100.
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10. 1126/science.1141478.
14. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, et al. Transcriptional and posttranslational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011; 108:5021-6; PMID:21385943; http://dx.doi.org/10.1073/pnas. 1016140108.
15. Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, et al. Phosphoinositide-3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 2011; (Epub ahead of print); PMID:21725367.
16. Gordon-Thomson C, Jones J, Mason RS, Moore GPM. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005; 15:21-8; PMID:15714117; http://dx.doi.org/10.1097/ 00008390-200502000-00005.
17. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors and potential applications. Semin Oncol 2007; 34:546-54; PMID:18083378; http://dx.doi.org/10. 1053/j.seminoncol.2007.09.011.
18. Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM, Pavan WJ. NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res 2009; 22:773-84; PMID:19659570; http://dx.doi.org/10.1111/j.1755-148X.2009.00616.x.
19. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2:31; PMID:19567914; http://dx.doi.org/10.1126/scisignal.2000352.
20. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485-94; PMID:20215504; http://dx.doi.org/10.1158/0008-5472.CAN- 09-3145.
21. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003.
22. Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, et al. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. J Cell Physiol 2011; PMID:22213458; http://dx.doi.org/10.1002/jcp.24037.
23. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, et al. Combination antibody treatment downregulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 2010; 107:13252-7; PMID:20616078; http://dx.doi.org/10.1073/pnas.0913476107.
24. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, et al. Synergistic downregulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 2005; 102:1915-20; PMID:15684082; http://dx.doi.org/10.1073/pnas.0409610102.
25. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 2009; 106:3294-9; PMID:19218427; http://dx.doi.org/10.1073/pnas.0812059106.
26. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008; 314:3093-106; PMID:18793634.
27. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 2009; 15:1575-84; PMID:19240169; http://dx.doi.org/10.1158/1078-0432. CCR-08-2628.
28. Cho HS, Leahy DJ. Structure of the extracellular region of ERBB3 reveals an interdomain tether. Science 2002; 209:1330-3; http://dx.doi.org/10.1126/ science.1074611.
29. Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 2011; 24:446-61; PMID:21320293; http://dx.doi.org/10.1111/j.1755-148X.2011.00836.x.
30. Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res 2009; 19:156-66; PMID:19434003; http://dx.doi.org/10.1097/CMR.0b013e32832c6339.
31. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008; 14:5188-97
32. Waterman H, Alroy I, Strano S, Seger R, Yarden Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J 1999; 18:3348-58; PMID:10369675; http://dx.doi.org/10.1093/emboj/18.12.3348.
33. Cao Z, Wu X, Yen L, Sweeney C, Carraway KL, 3rd. Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 2007; 27:2180-8; PMID:17210635; http://dx.doi.org/10.1128/MCB.01245-06.
34. Schmitz KR, Ferguson KM. Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 2009; 315:659-70; PMID:18992239; http://dx.doi.org/10.1016/j.yexcr.2008.10.008.
35. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532:253-68; PMID:12908564; http://dx.doi.org/10. 1007/978-1-4615-0081-0-21.
36. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535- 6108(04)00083-2.
37. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006; 66:3629-38; PMID:16585188; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-3204.